Zealand Pharma A/S (OTCMKTS:ZLDPF) & Pliant Therapeutics (NASDAQ:PLRX) Head to Head Review

Pliant Therapeutics (NASDAQ:PLRX) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Pliant Therapeutics and Zealand Pharma A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2	1	1	0	1.75
Zealand Pharma A/S	1	7	1	1	2.20

Pliant Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 157.51%. Given Pliant Therapeutics’ higher probable upside, research analysts plainly believe Pliant Therapeutics is more favorable than Zealand Pharma A/S.

Profitability

This table compares Pliant Therapeutics and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
Zealand Pharma A/S	58.86%	18.53%	17.14%

Risk and Volatility

Pliant Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Institutional and Insider Ownership

97.3% of Pliant Therapeutics shares are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Pliant Therapeutics and Zealand Pharma A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58 million	45.66	-$149.34 million	($1.49)	-0.78
Zealand Pharma A/S	$1.40 billion	2.66	$977.29 million	$6.03	8.59

Zealand Pharma A/S has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Zealand Pharma A/S beats Pliant Therapeutics on 9 of the 14 factors compared between the two stocks.

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.